Prospective Study of HPV Specific Immunotherapy in Patients With HPV Associated Head and Neck Squamous Cell Carcinoma (HNSCCa)
Phase of Trial: Phase I/II
Latest Information Update: 12 Mar 2018
At a glance
- Drugs MEDI 0457 (Primary)
- Indications Head and neck cancer; Human papillomavirus infections
- Focus Adverse reactions
- Sponsors Inovio Pharmaceuticals
- 06 Mar 2018 Status changed from active, no longer recruiting to completed.
- 10 Nov 2017 Results presented at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting 2017, according to an Inovio Pharmaceuticals media release.
- 11 Sep 2017 Planned End Date changed from 1 Apr 2017 to 1 Oct 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History